RGEN - Repligen Corp Stock Price, Fair Value and News

140.95USD+8.59 (+6.49%)Market Closed

Market Summary

USD140.95+8.59

Market Closed

6.49%

RGEN Stock Price

View Fullscreen

RGEN RSI Chart

RGEN Valuation

Market Cap

7.4B

Price/Earnings (Trailing)

498.3

Price/Sales (Trailing)

12.18

EV/EBITDA

67.03

Price/Free Cashflow

66.38

RGEN Price/Sales (Trailing)

RGEN Profitability

EBT Margin

4.96%

Return on Equity

0.75%

Return on Assets

0.52%

Free Cashflow Yield

1.51%

RGEN Fundamentals

RGEN Revenue

Revenue (TTM)

607.5M

Rev. Growth (Yr)

-17.14%

Rev. Growth (Qtr)

-2.82%

RGEN Earnings

Earnings (TTM)

14.8M

Earnings Growth (Yr)

-92.74%

Earnings Growth (Qtr)

108.22%

Breaking Down RGEN Revenue

Last 7 days

3.7%

Last 30 days

7.4%

Last 90 days

-20.6%

Trailing 12 Months

-24.8%

How does RGEN drawdown profile look like?

RGEN Financial Health

Current Ratio

6.35

Debt/Equity

0.26

Debt/Cashflow

0.29

RGEN Investor Care

Shares Dilution (1Y)

0.35%

Diluted EPS (TTM)

0.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	607.5M	0	0	0
2023	777.8M	729.3M	669.8M	638.8M
2022	734.1M	778.8M	801.3M	801.5M
2021	433.0M	508.5M	592.7M	670.5M
2020	285.7M	302.5M	327.1M	366.3M
2019	209.8M	232.8M	252.7M	270.2M
2018	155.5M	170.8M	183.7M	194.0M
2017	110.0M	113.3M	125.2M	141.2M
2016	87.8M	95.5M	100.4M	104.5M
2015	66.9M	72.8M	77.5M	83.5M
2014	66.0M	64.1M	60.4M	60.4M
2013	65.9M	67.9M	71.6M	68.2M
2012	36.3M	44.1M	50.6M	62.3M
2011	27.3M	27.9M	29.3M	29.4M
2010	21.0M	22.6M	24.1M	25.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Anthony J. Hunt
WEBSITE	repligen.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	2025

Repligen Corp Frequently Asked Questions

What is the ticker symbol for Repligen Corp? What does RGEN stand for in stocks?

RGEN is the stock ticker symbol of Repligen Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Repligen Corp (RGEN)?

As of Thu Jul 25 2024, market cap of Repligen Corp is 7.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RGEN stock?

You can check RGEN's fair value in chart for subscribers.

Is Repligen Corp a good stock to buy?

The fair value guage provides a quick view whether RGEN is over valued or under valued. Whether Repligen Corp is cheap or expensive depends on the assumptions which impact Repligen Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RGEN.

What is Repligen Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, RGEN's PE ratio (Price to Earnings) is 498.3 and Price to Sales (PS) ratio is 12.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Repligen Corp's stock?

In the past 10 years, Repligen Corp has provided 0.196 (multiply by 100 for percentage) rate of return.